Display options
Cite
Dumont A, Pannier D, Ducoulombier A, et al. ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. Springerplus. 2015;4:327doi: 10.1186/s40064-015-1053-0.
Dumont, A., Pannier, D., Ducoulombier, A., Tresch, E., Chen, J., Kramar, A., Révillion, F., Peyrat, J. P., & Bonneterre, J. (2015). ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. SpringerPlus, 4327. https://doi.org/10.1186/s40064-015-1053-0
Dumont, Aurélie, et al. "ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors." SpringerPlus vol. 4 (2015): 327. doi: https://doi.org/10.1186/s40064-015-1053-0
Dumont A, Pannier D, Ducoulombier A, Tresch E, Chen J, Kramar A, Révillion F, Peyrat JP, Bonneterre J. ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. Springerplus. 2015 Jul 07;4:327. doi: 10.1186/s40064-015-1053-0. eCollection 2015. PMID: 26180747; PMCID: PMC4493257.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2015 Jul 07;4:327. doi: 10.1186/s40064-015-1053-0. eCollection 2015.

ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.

SpringerPlus

Aurélie Dumont, Diane Pannier, Agnès Ducoulombier, Emmanuelle Tresch, Jinying Chen, Andrew Kramar, Françoise Révillion, Jean-Philippe Peyrat, Jacques Bonneterre

Affiliations

  1. Laboratoire d'Oncologie Moléculaire Humaine, Centre Oscar Lambret, 3 rue Frédéric Combemale, BP 307, 59020 Lille Cedex, France.
  2. Département de Sénologie, Centre Oscar Lambret, 3 rue Frédéric Combemale, BP 307, 59020 Lille Cedex, France.
  3. Unité de Méthodologie et Biostatistique, Centre Oscar Lambret, 3 rue Frédéric Combemale, BP 307, 59020 Lille Cedex, France.

PMID: 26180747 PMCID: PMC4493257 DOI: 10.1186/s40064-015-1053-0

Abstract

PURPOSE: Neoadjuvant chemotherapy (NCT) using anthracyclines and taxanes is a standard treatment for locally advanced breast cancer. Efficacy of NCT is however variable among patients and predictive markers are expected to guide the selection of patients who will benefit from NCT. A promising approach stand with polymorphisms located in genes encoding drug transporters, drug metabolizing enzymes and target genes which can affect drug efficacy. Our study investigated the potential of 37 polymorphisms to predict response to NCT in breast cancer.

METHODS: 118 women with breast adenocarcinoma were treated with FEC100 and taxotere. Genotyping was performed on germline DNA using the BioMark platform (Fluidigm). Pathological complete response (pCR) according to Sataloff criteria was correlated to clinical characteristics and genotypes using univariate and multivariate analyses.

RESULTS: 25 patients (21.2%) reached complete pathologic response. pCR rate is increased in SBRIII (p = 0.009), ER negative (p = 0.005) and triple negative (p = 0.006) tumors. pCR rate is significantly increased for patients carrying at least one variant allele for BRCA1, ERCC1 or SLCO1B3, and for patients homozygous for CYP1B1. The combination of ERCC1 and CYP1B1 polymorphisms is a potential predictor of NCT response in breast cancer (pCR rate reached 50 vs 21.2% for unselected patients), and particularly in ER + breast cancer subtype where pCR rate reached 41.2 vs 13.5% for unselected patients.

CONCLUSIONS: This study is the first to report ERCC1, BRCA1 and SLCO1B3 as markers of response to NCT in breast cancer. ERCC1/CYP1B1 combination might be of particular interest to predict response to NCT in breast cancer and particularly to help NCT indication for ER+ breast tumors.

Keywords: Breast cancer; CYP1B1; ERCC1; Neoadjuvant chemotherapy; Predictive factor; Single nucleotide polymorphism

References

  1. Lung Cancer. 2012 Jan;75(1):102-9 - PubMed
  2. J Urol. 2012 Feb;187(2):700-6 - PubMed
  3. BMC Cancer. 2008 Apr 11;8:97 - PubMed
  4. J Clin Oncol. 2001 Dec 1;19(23):4298-304 - PubMed
  5. J Gastrointest Surg. 2009 Aug;13(8):1411-21 - PubMed
  6. Carcinogenesis. 2008 Sep;29(9):1758-64 - PubMed
  7. Mutat Res. 2011 Mar 15;708(1-2):21-7 - PubMed
  8. Ann Oncol. 2004 Aug;15(8):1194-203 - PubMed
  9. Cancer Sci. 2010 May;101(5):1247-54 - PubMed
  10. Toxicology. 2005 Feb 14;207 (2):191-202 - PubMed
  11. Clin Lung Cancer. 2009 Mar;10(2):118-23 - PubMed
  12. Pharmacogenomics J. 2007 Oct;7(5):362-5 - PubMed
  13. Int J Oncol. 2008 May;32(5):1091-6 - PubMed
  14. Cancer Res. 2000 Jul 1;60(13):3440-4 - PubMed
  15. Carcinogenesis. 1999 Aug;20(8):1607-13 - PubMed
  16. Cancer Sci. 2009 Feb;100(2):278-83 - PubMed
  17. Clin Cancer Res. 2005 Sep 1;11(17):6212-7 - PubMed
  18. Mol Cancer Ther. 2008 Jan;7(1):19-26 - PubMed
  19. J Am Coll Surg. 1995 Mar;180(3):297-306 - PubMed
  20. J Gastrointest Surg. 2012 Jan;16(1):26-34; discussion 34 - PubMed
  21. Cancer Biol Ther. 2005 Aug;4(8):815-8 - PubMed
  22. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  23. Cancer Chemother Pharmacol. 2011 Jun;67(6):1471-8 - PubMed
  24. Pharmacogenetics. 2000 Jun;10(4):343-53 - PubMed
  25. Ann Surg Oncol. 2012 May;19(5):1508-16 - PubMed
  26. Clin Cancer Res. 2004 Oct 1;10(19):6622-8 - PubMed
  27. Hematol Oncol Clin North Am. 2013 Aug;27(4):767-84, ix - PubMed
  28. J Biol Chem. 2000 Jul 28;275(30):23161-8 - PubMed
  29. Br J Clin Pharmacol. 2012 Apr;73(4):606-18 - PubMed
  30. Anticancer Res. 2000 Mar-Apr;20(2A):645-52 - PubMed
  31. BMC Cancer. 2010 Sep 27;10:511 - PubMed
  32. Biochem Pharmacol. 2001 Jul 15;62(2):207-12 - PubMed
  33. Clin Cancer Res. 2002 Jul;8(7):2286-91 - PubMed
  34. J Clin Oncol. 2008 Feb 10;26(5):778-85 - PubMed

Publication Types